In the last trading session, 1.7 million Sagimet Biosciences Inc (NASDAQ:SGMT) shares changed hands as the company’s beta touched 3.33. With the company’s per share price at $7.87 changed hands at -$0.83 or -9.54% during last session, the market valuation stood at $241.41M. SGMT’s last price was a discount, traded about -32.53% off its 52-week high of $10.43. The share price had its 52-week low at $1.73, which suggests the last value was 78.02% up since then. When we look at Sagimet Biosciences Inc’s average trading volume, we note the 10-day average is 2.33 million shares, with the 3-month average coming to 1.48 million.
Analysts gave the Sagimet Biosciences Inc (SGMT) stock a consensus recommendation rating of Buy, calculated at a mean rating of 1.00. If we narrow down to specifics, the data shows that 0 out of 5 analysts rate the stock as a Sell, with a further 0 assigning it an Overweight rating. Of the remaining, 1 recommended SGMT as a Hold, 4 felt it is a Buy and 0 rated the stock as Underweight.
Sagimet Biosciences Inc (NASDAQ:SGMT) trade information
Instantly SGMT was in red as seen at the end of in last trading. With action -9.75%, the performance over the past five days has been red. The company’s shares are showing year-to-date upside of 90.10%, with the 5-day performance at -9.75% in the red. However, in the 30-day time frame, Sagimet Biosciences Inc (NASDAQ:SGMT) is 131.47% up. Looking at the short shares, we see there were 3.81 million shares sold at short interest cover period of 1.54 days.
The consensus price target for the stock as assigned by Wall Street analysts is 6, meaning bulls need a downside of -31.17% from its current market value. According to analyst projections, SGMT’s forecast low is 6 with 6 as the target high. To hit the forecast high, the stock’s price needs a 23.76% surge from its current level, while the stock would need to tank 23.76% for it to hit the projected low.
Looking at the company’s year-on-year earnings, data shows that the past 5-year has an earnings growth rate of -16.85%. The 2025 estimates are for Sagimet Biosciences Inc earnings to decrease by -54.40%, but the outlook for the next 5-year period is at -25.74% per year.
SGMT Dividends
Sagimet Biosciences Inc is expected to release its next quarterly earnings report on 2025-May-08.
Sagimet Biosciences Inc (NASDAQ:SGMT)’s Major holders
If we look at who the major shareholders are, we find that insiders hold 13.31% of Sagimet Biosciences Inc shares while 45.88% of the shares are in the hands of institutional holders. The share float percentage for the stock currently stands at 52.93%. There are 45.88% institutions holding the Sagimet Biosciences Inc stock share, with POINT72 ASSET MANAGEMENT, L.P. the top institutional holder. As of 2024-06-30, the company held 7.414% of the shares, roughly 2.37 million SGMT shares worth $8.09 million.
NEA MANAGEMENT COMPANY, LLC holds the second largest percentage of outstanding shares, with 6.2677% or 2.0 million shares worth $6.84 million as of 2024-06-30.
Among Mutual Funds, the top two as of Mar 31, 2025 were VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund and BlackRock Health Sciences Term Trust . With 763.99 shares estimated at $6.01 million under it, the former controlled 2.49% of total outstanding shares. On the other hand, BlackRock Health Sciences Term Trust held about 1.33% of the shares, roughly 408.12 shares worth around $3.21 million.
